Risultati per: Aspirina e Omega 3 possono ridurre il rischio di cancro al colon

Crollano titoli in Borsa delle aziende del settore

Lo affermano i National Institutes of Health degli Stati Uniti

Il programma viene esteso fino alla fascia 70-74 anni

Introduction
The standard of care for stage III colon cancer is 3 or 6 months of double-drug regimen chemotherapy following radical surgery. However, patients with positive circulating tumour DNA (ctDNA) exhibit a high risk of recurrence risk even if they receive standard adjuvant chemotherapy. The potential benefit of intensified adjuvant chemotherapy, oxaliplatin, irinotecan, leucovorin and fluoropyrimidine (FOLFOXIRI), for ctDNA-positive patients remains to be elucidated.

Methods and analysis
This multicentre phase II randomised controlled trial aims to investigate the utility of ctDNA in monitoring chemosensitivity and to preliminarily assess whether intensified chemotherapy with FOLFOXIRI can increase ctDNA clearance and improve survival outcomes. A total of 60 eligible patients with stage III colon cancer exhibiting postoperatively positive ctDNA before and after two cycles of oxaliplatin and capecitabine (XELOX) will be randomly assigned to continue five additional cycles of XELOX (control arm) or switch to eight cycles of FOLFOXIRI (experimental arm). This sequential approach is designed to escalate treatment for patients with persistent ctDNA positivity while avoiding overtreatment in those who may respond well to standard chemotherapy. The primary endpoint is the change in ctDNA concentration, defined as the difference between the ctDNA concentration measured after two cycles of XELOX and after the completion or termination of chemotherapy. Secondary endpoints include the ctDNA clearance rate, 2-year disease-free survival, distant metastasis-free survival, chemotherapy-related side effects and quality of life.

Ethics and dissemination
This trial has been approved by the Ethics Committee of the West China Hospital, Sichuan University (approval number: 20231998). The findings will be disseminated through peer-reviewed publications and presentations at scientific conferences.

Trial registration number
ClinicalTrials.gov (NCT06242418, registered on 27 January 2024).

‘Non favoriamo i privati. A febbraio piattaforma monitoraggio’

Dal 30 dicembre grazie all’aggiornamento dei Livelli essenziali di assistenza diventano esenti o con pagamento del ticket 16 prestazioni ad hoc.

Ricoverato il 60%, il 13,5 in terapia intensiva, mortalità 10,6%

La disfunzionalità dell’adipe si riflette sui tessuti arteriosi, cardiaci e renali e queste interconnessioni rappresentano una sfida importante per il Ssn, ma anche un’opportunità per migliorare la presa in cura dei pazienti con patologie complesse

Geriatri, ‘raccomandare i vaccini potenziati’. Invito a immunizzarsi, ‘si è ancora in tempo’

Emilia più attrattiva. Cittadinanzattiva, nodo malattie croniche

Emilia più attrattiva. Cittadinanzattiva, nodo malattie croniche

Background
Colonic motility in constipation can be assessed non-invasively using MRI.

Objective
To compare MRI with high-resolution colonic manometry (HRCM) for predicting treatment response.

Design
Part 1: 44 healthy volunteers (HVs), 43 patients with irritable bowel syndrome with constipation (IBS-C) and 37 with functional constipation (FC) completed stool diaries and questionnaires and underwent oral macrogol (500–1000 mL) challenge. Whole gut transit time (WGTT), segmental colonic volumes (CV), MRI-derived Motility Index and chyme movement by ‘tagging’ were assessed using MRI and time to defecation after macrogol recorded. Left colonic HRCM was recorded before and after a 700 kcal meal. Patients then proceeded to Part 2: a randomised cross-over study of 10-days bisacodyl 10 mg daily versus hyoscine 20 mg three times per day, assessing daily pain and constipation.

Results
Part 1: Total CVs median (range) were significantly greater in IBS-C (776 (595–1033)) and FC (802 (633–951)) vs HV (645 (467–780)), p

Cnr, nuovo approccio potrebbe migliore sopravvivenza pazienti

Cartabellotta, “tagli a spesa causano non pochi problemi”

Consumo occasionale di dolciumi meglio dell’astinenza completa

Per la scienza il cioccolato – rigorosamente fondente e non al latte – è anche un cibo amico della salute